Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11442172 | 0.77 | POLB (0.31) | POLB | |
| SCHEMBL4722124 | 0.76 | RIPK1 (0.34) | HMGCRCHRM1TBXA2RADRA1AALDH1A1 | |
| SCHEMBL6264890 | 0.74 | TSHR (0.32) | HMGCRCHRM1TBXA2RADRA1AALDH1A1 | |
| SCHEMBL1144163 | 0.72 | THRA (0.32) | ALDH1A1TSHR | |
| SCHEMBL8853478 | 0.70 | MMP8 (0.32) | — | |
| SCHEMBL16328355 | 0.70 | TDP1 (0.35) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| Bicarbonate SCHEMBL26105671 | 0.70 | TSHR (0.41) | POLBHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL13106870 | 0.69 | ACLY (0.32) | ALDH1A1TSHR | |
| SCHEMBL497097 | 0.67 | TSHR (0.39) | HMGCRCHRM1TBXA2RADRA1AALDH1A1 | |
| SCHEMBL2379607 | 0.67 | FFAR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472380-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | PLACON THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20170349615-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9771387-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | PLACON THERAPEUTICS (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160152646-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| WO-2015009841-A2 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | BLEND THERAPEUTICS (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349615-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | TP53, PDCD1LG2, IDH1 | POLB 1212/4885HMGCR 2122/4885CHRM1 4824/4885 |
| US-20160152646-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | TP53, PDCD1LG2, IDH1 | POLB 1212/4885HMGCR 2122/4885CHRM1 4824/4885 |
| US-10472380-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | TP53, PDCD1LG2, IDH1 | POLB 1212/4885HMGCR 2122/4885CHRM1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.